ID: ALA5170266

Max Phase: Preclinical

Molecular Formula: C26H28N8O2

Molecular Weight: 484.56

Representations

Canonical SMILES:  CN1CCN(c2ccc3[nH]c(Cc4nc5c(c(=O)[nH]c(=O)n5C)n4Cc4ccccc4)nc3c2)CC1

Standard InChI:  InChI=1S/C26H28N8O2/c1-31-10-12-33(13-11-31)18-8-9-19-20(14-18)28-21(27-19)15-22-29-24-23(25(35)30-26(36)32(24)2)34(22)16-17-6-4-3-5-7-17/h3-9,14H,10-13,15-16H2,1-2H3,(H,27,28)(H,30,35,36)

Standard InChI Key:  AFWMZFRRHKPQLS-UHFFFAOYSA-N

Molecule Features

Natural Product: No

Oral: No

Chemical Probe: No

Parenteral: No

Molecule Type:

Topical: No

First In Class: No

Black Box: No

Chirality: No

Availability: No

Prodrug: No

Properties

Molecular Weight: 484.56

Molecular Weight (Monoisotopic): 484.2335

AlogP: 1.69

#Rotatable Bonds: 5

Polar Surface Area: 107.84

Molecular Species: NEUTRAL

HBA: 8

HBD: 2

#RO5 Violations: 0

HBA (Lipinski): 10

HBD (Lipinski): 2

#RO5 Violations (Lipinski): 0

CX Acidic pKa: 9.28

CX Basic pKa: 7.88

CX LogP: 2.31

CX LogD: 1.85

Aromatic Rings: 5

Heavy Atoms: 36

QED Weighted: 0.39

Np Likeness Score: -1.63

References

1. Specker E, Matthes S, Wesolowski R, Schütz A, Grohmann M, Alenina N, Pleimes D, Mallow K, Neuenschwander M, Gogolin A, Weise M, Pfeifer J, Ziebart N, Heinemann U, von Kries JP, Nazaré M, Bader M..  (2022)  Structure-Based Design of Xanthine-Benzimidazole Derivatives as Novel and Potent Tryptophan Hydroxylase Inhibitors.,  65  (16.0): [PMID:35921615] [10.1021/acs.jmedchem.2c00598]

Source

Source(1):

• Scientific Literature